id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
DEA-2022-0068-0005,DEA,DEA-2022-0068,FINAL SIGNED - Fenfluramine Letter and 8FA review 16Apr2021,Supporting & Related Material,,2023-01-03T05:00:00Z,2023,1,,,2023-01-03T13:21:30Z,,0,0,090000648557e6b8
DEA-2022-0068-0004,DEA,DEA-2022-0068,DEA945 Eight Factor Analysis Fenfluramine 012022,Supporting & Related Material,,2023-01-03T05:00:00Z,2023,1,,,2023-01-03T13:21:26Z,,0,0,090000648556a0f0
DEA-2022-0068-0003,DEA,DEA-2022-0068,Schedules of Controlled Substances: Removal of Fenfluramine from Control,Rule,,2022-12-23T05:00:00Z,2022,12,2022-12-23T05:00:00Z,,2022-12-23T13:05:30Z,2022-27400,0,0,0900006485550c29
DEA-2022-0068-0001,DEA,DEA-2022-0068,Schedules of Controlled Substances: Removal of Fenfluramine From Control,Proposed Rule,,2022-07-19T04:00:00Z,2022,7,2022-07-19T04:00:00Z,2022-08-19T03:59:59Z,2022-07-28T01:00:56Z,2022-15335,0,0,09000064851d1a59